ADHD is no longer considered just a childhood diagnosis. Compared to several years ago, there is now a much greater awareness around ADHD among American adults. Affecting approximately 5% of children, ADHD persists or is newly identified in about 2.5% of adults. However, there are significant diagnostic disparities—women, girls, and people of color are thought to be underdiagnosed. And clinical identification rates for African American and Latino groups are markedly lower than for Caucasian populations. Primary care can play a critical role in closing this gap by accurately identifying and managing the condition.
Diagnosing adults—defined in this case as those aged 17 and older—requires meeting clear criteria beyond simply displaying symptoms. For a formal diagnosis, symptoms must have been present before age 12, occur in two or more different settings, and cause substantial impairment. Without clear impairment, the symptoms do not constitute a disorder. Furthermore, these nonspecific symptoms cannot be better explained by medical conditions or other psychiatric conditions, such as depression or anxiety.
The presentation of ADHD changes as patients age. Unlike children, who often exhibit overt impulsivity and hyperactivity, adults tend to internalize these symptoms, which frequently disrupts their work performance and interpersonal relationships. Many, if not most, people do not “grow out” of ADHD symptoms, and may benefit from treatment across the lifespan. Additionally, women and girls are more likely to present primarily with inattentive symptoms rather than hyperactive ones.
Clinical evaluation remains the gold standard for diagnosing ADHD in adults. While screening tools like the Adult ADHD Self-Report Scale (ASRS) can be used, they should not be considered diagnostic instruments. Routine screening questions can include:
Assessments must comprehensively review current medications, medical conditions, family history and substance use. Previous evaluations or treatment history for ADHD should be obtained when available. Neuropsychological testing is not beneficial for most patients and can actually serve as a barrier to treatment.
The etiology of ADHD is primarily genetic. However, other contributing factors include perinatal stress, low birth weight, traumatic brain injury, maternal smoking during pregnancy, and severe early deprivation. Clinically, this can manifest as pronounced deficits in executive function, specifically impacting a patient's vigilance, working memory, planning, and response inhibition.
When treating Adult ADHD, stimulants are generally considered the most effective first-line option. Initial response rates can reach up to 85% if both methylphenidate and amphetamine classes are trialed. Extended-release (XR) formulations are usually preferred over immediate-release formulations because they are equally effective, lessen the executive function burden of multiple daily doses, and carry a lower risk for abuse and diversion. For example, medications like Vyvanse (lisdexamfetamine) provide once-a-day dosing and have a lower abuse liability.
Monitoring while on stimulants includes regularly checking blood pressure and heart rate, and by assessing for side effects like insomnia or appetite changes. It may also include a controlled drug agreement, regular urine drug screening, and checking the state Prescription Drug Monitoring Program (PDMP) for controlled drugs. A baseline EKG is only necessary if there is a personal or family history of cardiovascular defects prior to starting a stimulant. Stimulants carry contraindications, including absolute contraindication for angle-closure glaucoma and additional caution for patients with conditions like prolonged QT interval, Brugada syndrome, or Wolff-Parkinson-White syndrome. They also pose risks for exacerbating anxiety, triggering mania, or inducing psychosis.
Non-stimulants can be an option for patients who are not stimulant candidates, and can be beneficial for patients with comorbidities. Non-stimulants can also be used in combination with stimulants in some cases. Bupropion can assist with comorbid depression and smoking cessation, while atomoxetine is beneficial for generalized and social anxiety. Clonidine is a viable choice for patients experiencing anxiety, insomnia, or PTSD.
Medical treatment should always be paired with therapeutic and lifestyle interventions, including:
There are seemingly endless combinations for medication and treatment options to help support adult patients with ADHD. By deeply integrating behavioral health with medical care, we extend much needed support to both patients and their treatment team.